Skip to main content

Advertisement

SpringerLink
Log in

Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

The factors underlying the variability in the results of randomized, placebo-controlled clinical trials (RPCCT) assessing pharmacological interventions for adults with attention deficit hyperactivity disorder (ADHD) are not fully understood.

Methods

A systematic review and meta-analysis of RPCCT comparing pharmacological treatment and placebo in adults with ADHD was carried out. The study outcomes were all-cause treatment discontinuation, efficacy on ADHD symptoms, and safety. Patient-, intervention-, and study design-related covariates were collected. Meta-regression methods were applied.

Results

Forty-four studies involving 9952 patients were included. All-cause treatment discontinuation was slightly higher with pharmacological treatment than with placebo (odds ratio (OR) = 1.18; 95 % confidence interval (CI) 1.02, 1.36; p = 0.003). A better outcome on all-cause treatment discontinuation was observed in studies that provided concomitant psychotherapy when compared to those that did not (rate of OR (ROR) = 0.68, p = 0.048). Pharmacological treatment was efficacious for reducing ADHD symptoms (standardized mean difference (SMD) = 0.45; 95 % CI 0.37, 0.52; p < 0.00001), with stronger intervention effects found in studies investigating stimulant drugs (difference of SMD (Diff SMD) = 0.18, p = 0.017), in shorter studies (Diff SMD = −0.01, p = 0.044), and when clinician-rated scales were used (Diff SMD = 0.44, p < 0.0001). Pharmacological treatment was associated with more frequent adverse events (AEs) (OR = 2.29; 95 % CI 1.97, 2.66; p = 0.006). Studies with a lead-in phase and with a higher proportion of patients previously treated with stimulants were associated with a better safety outcome (ROR = 0.59, p = 0.017; ROR = 0.98, p = 0.036, respectively).

Conclusion

Pharmacological treatment provides mild symptom improvement but is associated with frequent AEs and higher treatment discontinuation than placebo, particularly when no concomitant psychotherapy is administered. Stimulants appear more efficacious than non-stimulant drugs and the former should be preferred over the latter. The efficacy of pharmacological treatment should be monitored over time because it may decrease progressively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Asherson P, Bushe C, Saylor K, Tanaka Y, Deberdt W, Upadhyaya H (2014) Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol 28:837–46

    Article  PubMed  PubMed Central  Google Scholar 

  • Bae JM (2014) Meta-epidemiology. Epidemiol Health 25:36, e2014019

    Google Scholar 

  • Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101

    Article  PubMed  CAS  Google Scholar 

  • Berkey CS, Hoaglin DC, Mosteller F, Colditz GA (1995) A random effects regression model for meta-analysis. Stat Med 14:395–411

    Article  PubMed  CAS  Google Scholar 

  • Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M (2006) Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 67:524–40

    Article  PubMed  Google Scholar 

  • Biederman J, Petty CR, Woodworth KY, Lomedico A, Hyder LL, Faraone SV (2012) Adult outcome of attention-deficit/hyperactivity disorder: a controlled 16-year follow-up study. J Clin Psychiatry 73:941–50

    Article  PubMed  Google Scholar 

  • Bolea-Alamañac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, Heal D, Müller U, Nash J, Santosh P, Sayal K, Sonuga-Barke E, Young SJ, British Association for Psychopharmacology (2014) Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 28:179–203

    Article  PubMed  Google Scholar 

  • Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA) (2011) Canadian ADHD practice guidelines. 3rd edn. Toronto

  • Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, Casas M (2011) Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 25:157–69

    Article  PubMed  CAS  Google Scholar 

  • Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:110–129

    Google Scholar 

  • Cohen J (1988) Statistical power analysis in the behavioural sciences, 2nd edn. Lawrence Erlbaum Associated, Hillsdale

    Google Scholar 

  • Cunill R, Castells X, Tobias A, Capellà D (2015) Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. J Psychopharmacol 29:15–23

    Article  PubMed  CAS  Google Scholar 

  • Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG (2015) Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet S0140–6736(14):61684–6. doi:10.1016/S0140-6736(14)61684-6

    Google Scholar 

  • Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P (2011) Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. Ann Intern Med 155:39–51

    Article  PubMed  Google Scholar 

  • Epstein T, Patsopoulos NA, Weiser M (2014) Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 9:CD005041. doi:10.1002/14651858.CD005041.pub2

    PubMed  Google Scholar 

  • Higgins JPT, Green S (2011a) The Cochrane Collaboration tool for assessing risk of bias. In: Cochrane handbook for systematic reviews of interventions version 5.1.0. [updated March 2011]. The Cochrane Collaboration Available from www.cochrane-handbook.org

  • Higgins JPT, Green S (2011b) How to include multiple groups from one study. In: Higgins JPT, Green S (eds), Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration Available from www.cochrane-handbook.org

  • Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analysis. BMJ 327:557–560

    Article  PubMed  PubMed Central  Google Scholar 

  • Jerome L, Segal A, Habinski L (2006) What we know about ADHD and driving risk: literature review, meta-analysis and critique. J Can Adolesc Psychiatry 15:105–25

    Article  Google Scholar 

  • Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky AM (2006) The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163:716–23

    Article  PubMed  PubMed Central  Google Scholar 

  • Klein RG, Mannuzza S, Olazagasti MA, Roizen E, Hutchison JA, Lashua EC, Castellanos FX (2012) Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry 69:1295–303

    Article  PubMed  PubMed Central  Google Scholar 

  • Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S (2009) Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 23:733–44

    Article  PubMed  CAS  Google Scholar 

  • Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P (2010) European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 10:67

    Article  PubMed  PubMed Central  Google Scholar 

  • Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV (2006) Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 81:137–48

    Article  PubMed  CAS  Google Scholar 

  • Levin FR, Evans SM, Brooks DJ, Garawi F (2007) Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 87:20–9

    Article  PubMed  CAS  Google Scholar 

  • Maneeton N, Maneeton B, Srisurapanont M, Martin SD (2011) Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci 65:611–7

    Article  PubMed  Google Scholar 

  • Maneeton N, Maneeton B, Suttajit S, Reungyos J, Srisurapanont M, Martin SD (2014) Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD. Drug Des Devel Ther 8:1685–93

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Mannuzza S, Klein RG, Moulton JL 3rd (2008) Lifetime criminality among boys with attention deficit hyperactivity disorder: a prospective follow-up study into adulthood using official arrest records. Psychiatry Res 160:237–46

    Article  PubMed  PubMed Central  Google Scholar 

  • MTA Cooperative Group (2004) National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113:762–769

    Article  Google Scholar 

  • National Institute for Health and Clinical Excellence (NICE) (2008) Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. Clinical guidelines CG72

  • Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D, Atomoxetine/Methylphenidate Comparative Study Group (2008) Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 165:721–30

    Article  PubMed  Google Scholar 

  • Pérez-Mañá C, Castells X, Torrens M, Capellà D, Farre M (2013) Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev 9:CD009695. doi:10.1002/14651858.CD009695.pub2

    PubMed  Google Scholar 

  • Peterson K, McDonagh MS, Fu R (2008) Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl) 197:1–11

    Article  CAS  Google Scholar 

  • Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA (2015) Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry 56:345–65

    Article  PubMed  Google Scholar 

  • Review Manager (RevMan) Version 5.3 (2014) Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration

  • Schwartz S, Correll CU (2014) Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry 53:174–87

    Article  PubMed  Google Scholar 

  • Seixas M, Weiss M, Müller U (2012) Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol 26:753–65

    Article  PubMed  Google Scholar 

  • Sharf J, Primavera LH, Diener MJ (2010) Dropout and therapeutic alliance: a meta-analysis of adult individual psychotherapy. Psychotherapy (Chic) 47:637–45

    Article  Google Scholar 

  • Simon V, Czobor P, Bálint S, Mészáros A, Bitter I (2009) Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 194:204–11

    Article  PubMed  Google Scholar 

  • Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S (2005) A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57:456–63

    Article  PubMed  CAS  Google Scholar 

  • StataCorp (2011) Stata statistical software: release 12 [Computer program] (2011) College Station, TX: StataCorp

  • Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 339:b2880. doi:10.1136/bmj.b2880

    Article  PubMed  PubMed Central  Google Scholar 

  • Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA (2003) The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29:15–31

    Article  PubMed  Google Scholar 

  • Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S (1999) Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 66:295–305

    Article  PubMed  CAS  Google Scholar 

  • Taylor A, Deb S, Unwin G (2011) Scales for the identification of adults with attention deficit hyperactivity disorder (ADHD): a systematic review. Res Dev Disabil 2:924–38

    Article  Google Scholar 

  • Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI (2011) Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry 72:1660–8

    Article  PubMed  CAS  Google Scholar 

  • Undurraga J, Baldessarini RJ (2012) Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 37:851–64

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C, 31001074–ATT2001 Study Investigators (2012) Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs 26:421–34

    Article  PubMed  CAS  Google Scholar 

  • Weiss MD, Gadow K, Wasdell MB (2006) Effectiveness outcomes in attention-deficit/hyperactivity disorder. J Clin Psychiatry 67:38–45

    Article  PubMed  Google Scholar 

  • Willcutt EG (2012) The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 9:490–9

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, Barcelona, Spain

    R. Cunill

  2. Clinical Pharmacology Unit, TransLab Research Group, Department of Medical Sciences, Universitat de Girona, Emili Grahit, 77, 17071, Girona, Spain

    X. Castells & D. Capellà

  3. Institute of Environmental Assessment and Water Research (IDAEA), Spanish Council for Scientific Research (CSIC), Barcelona, Spain

    A. Tobias

Authors
  1. R. Cunill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X. Castells
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Tobias
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Capellà
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X. Castells.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 665 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cunill, R., Castells, X., Tobias, A. et al. Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients. Psychopharmacology 233, 187–197 (2016). https://doi.org/10.1007/s00213-015-4099-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-015-4099-3

Keywords

Search

Navigation